Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 1

Conditions

Thyroid Neoplasms 1Neoplasm Metastasis 1Differentiated Thyroid Carcinoma 1

Interventions

Magnetic Resonance Spectroscopy 5Specimen Handling 4Nivolumab 3ulixertinib 2dabrafenib 2binimetinib 2Surveys and Questionnaires 2Sunitinib 2Ipilimumab 2Immunoglobulin G 2Disulfides 2Cetuximab 2CTLA-4 Antigen 2Biopsy 2trastuzumab deruxtecan 1trastuzumab biosimilar HLX02 1trametinib 1tipifarnib 1temsirolimus 1selpercatinib 1sapanisertib 1repotrectinib 1relatlimab 1pertuzumab 1palbociclib 1osimertinib 1omipalisib 1larotrectinib 1ipatasertib 1gallium Ga 68 dotatate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Thyroid Neoplasms × Iodine-124 × 30 days × Clear all
NCT03841617 2026-06-05

The Use of 124-I-PET/CT Whole Body and Lesional Dosimetry in Differentiated Thyroid Cancer

National Institutes of Health Clinical Center (CC)

Phase 2 Recruiting
30 enrolled
Head & Neck

Neoplasm Metastasis, Thyroid Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡